Dr. Daniel Eduardo Alape Moya, MD

Dr. Alape Moya practices at Allergy & Asthma Centers of Cape Cod in Yarmouth Port, Massachusetts.

Dr. Alape Moya's NPI, 1477058816, was assigned on March 28, 2018. Dr. Alape Moya holds Massachusetts license FA3447922.

Dr. Alape Moya's primary practice is Allergy & Asthma Centers of Cape Cod, at 244 Willow St, Yarmouth Port, MA 02675 in Barnstable County. The practice phone is (508) 362-0099.

Dr. Alape Moya's primary practice is Allergy & Asthma Centers of Cape Cod in Yarmouth Port, Massachusetts. Dr. Alape Moya is also affiliated with Cape Cod Hospital. The medical group on file is Select Physical Therapy. Dmand AI also links Dr. Alape Moya to 1 more hospital, 3 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Alape Moya practices, 5 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Alape Moya's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Alape Moya is licensed in Massachusetts.

CMS data shows 185 Medicare services from Dr. Alape Moya across 5 procedure codes in 2024, for 150 Medicare patients. Medicare paid $22,714 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 150 Medicare patients who saw Dr. Alape Moya in 2024. The largest group is 75 to 84, with 62 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 23% are also on Medicaid. Their average risk score is 1.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Alape Moya's median patient age at 75, with 46% women.

In 2024, Dr. Alape Moya wrote 376 Medicare Part D claims for 125 patients. 47% of them were for generic drugs. CMS names the drug for 249 of them, across 11 drugs with 11 or more claims each, at $89,508 in total drug cost. In 2023, CMS named 303 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Alape Moya for performance year 2024, reported as part of a group. Dr. Alape Moya accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Alape Moya as offering telehealth.

Dmand AI links 2 papers to Dr. Alape Moya, published from 2020 to 2024. Dr. Alape Moya's most frequent co-authors are Richard N. Channick, MD, Sebastian Fernandez-Bussy, MD and Van Kim Holden, MD.

CMS Open Payments shows 22 general payments to Dr. Alape Moya from 10 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 87% of the total. AstraZeneca Pharmaceuticals LP paid the most, $218.